GW Pharmaceuticals initiates phase 3 study of Nabiximols for multiple sclerosis-associated spasticity

GW Pharmaceuticals initiates phase 3 study of Nabiximols for multiple sclerosis-associated spasticity. (Credit: PublicDomainPictures from Pixabay)